Defining new paradigms for the treatment of pancreatic cancer (Q37860976)

24 August 2017

1 reference

title

Defining new paradigms for the treatment of pancreatic cancer (English)

1 reference

24 August 2017

1 reference

Khaldoun Almhanna

1

1 reference

PubMed ID

21461670

24 August 2017

Philip A Philip

series ordinal

2

1 reference

24 August 2017

1 June 2011

1 reference

Current Treatment Options in Oncology

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

2

1 reference

24 August 2017

111-125

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-011-0150-8

24 August 2017

0 references

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Pathways for aberrant angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

The epidermal growth factor receptor in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Development and characterization of gemcitabine-resistant pancreatic tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Pancreatic cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0150-8

Immune cell functions in pancreatic cancer

21 January 2018

1 reference

12 December 2020

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

1 reference

12 December 2020

Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.

1 reference

12 December 2020

Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis

1 reference

12 December 2020

Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo

1 reference

12 December 2020

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

1 reference

12 December 2020

p53 protein expression as prognostic factor in human pancreatic cancer

1 reference

12 December 2020

AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.

1 reference

12 December 2020

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

1 reference

12 December 2020

Cellular functions regulated by Src family kinases

1 reference

12 December 2020

Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma

1 reference

12 December 2020

Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent

1 reference

12 December 2020

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma

1 reference

12 December 2020

Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53

1 reference

12 December 2020

10.1007/S11864-011-0150-8

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21461670